Stock analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Down 2.4 %
Shares of NASDAQ:PULM opened at $2.00 on Friday. The company has a market cap of $7.30 million, a PE ratio of -0.83 and a beta of 1.00. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The firm has a 50-day simple moving average of $2.06 and a 200 day simple moving average of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. The company had revenue of $1.55 million during the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- Buy P&G Now, Before It Sets A New All-Time High
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Bank Stocks – Best Bank Stocks to Invest In
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Insider Trades May Not Tell You What You Think
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
